UChicago Medicine-led team selected for the 2022 Michael & Lori Milken Family Foundation-PCF Challenge Award to develop novel immunotherapy approaches in advanced prostate cancer

The Prostate Cancer Foundation (PCF) has awarded a $1 million grant to a renowned specialist at the University of Chicago Medicine Comprehensive Cancer Center.

Newly identified personalized immunotherapy combination treats an aggressive form of advanced prostate cancer

A combination treatment that targets the immune system helps treat aggressive prostate cancers that don’t respond to conventional therapies.

Triple-drug therapy for post-transplant management of multiple myeloma

Promising results from an ongoing clinical trial a three-drug treatment may improve survival in patients with newly diagnosed multiple myeloma who have undergone preliminary treatment followed by a stem cell transplant.

Understanding How the Perception of Risks and Benefits Influence Cancer Clinical Trial Withdrawal Outcomes

While people with cancer have options to participate in cancer clinical trials (CCTs), it can be challenging when they encounter difficulties enrolling and remaining in the trial. Trial withdrawal, although every participant’s right, can thwart study goals and hamper advancing novel treatments.

Montefiore Einstein Cancer Center Finds CAR-T Therapy Effective in Black and Hispanic Patients

CAR-T therapy, a form of immunotherapy that revs up T-cells to recognize and destroy cancer cells, has revolutionized the treatment of blood cancers, including certain leukemias, lymphomas, and most recently, multiple myeloma. However, Black and Hispanic people were largely absent from the major clinical trials that led to the U.S. Food and Drug Administration approval of CAR-T cell therapies.

Are Too Many Phase III Cancer Clinical Trials Set Up to Fail?

New research in JNCCN finds four out of five cancer therapies tested in Phase III trials do not achieve clinically-meaningful benefit in prolonging survival, and is the first study to quantify the number of false-positive, false-negative, and true-negative trial results.

American Society for Radiation Oncology (ASTRO) to host in-person Annual Meeting in Chicago, October 24-27

Registration opens today for the American Society for Radiation Oncology’s (ASTRO) 63rd Annual Meeting, which will return to an in-person conference at McCormick Place West in Chicago, October 24-27, 2021. Media resources and registration are available at www.astro.org/astro2021press, and general registration is available at www.astro.org/annualmeeting.

Henry Ford Health System is First in the U.S. to Perform Procedure Using CG-100 Device for Colorectal Cancer Patients

Henry Ford Health System is the first in the country to perform a procedure using the CG-100 intraluminal device, which is temporarily inserted into the gastrointestinal tract and designed to reduce diverting stoma rates, and the need for an ostomy bag, in patients undergoing gastrointestinal resection procedures due to colorectal cancer treatment.

Mount Sinai Researchers Discover How to Boost Efficacy of Vaccine Designed to Prevent Melanoma Recurrence

A vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system cells called dendritic cells, according to phase 2 clinical trial results published in Nature Cancer in November.

Grounded in Science

Doctors face a difficult decision when they must choose a drug combination that will benefit the person sitting before them in an exam room. Statistics can’t show how any one person will respond to a reatment.works in people. Dr. Sarah Adams is using a $1.2M to find better ways to predict which women will benefit from her drug combination, now in clinical trials.